Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Retinoic acid receptor gamma | Starlite/ChEMBL | References |
Rattus norvegicus | Retinoic acid receptor alpha | Starlite/ChEMBL | References |
Rattus norvegicus | Retinoid X receptor gamma | Starlite/ChEMBL | References |
Rattus norvegicus | Peroxisome proliferator-activated receptor gamma | Starlite/ChEMBL | References |
Rattus norvegicus | Retinoid X receptor beta | Starlite/ChEMBL | References |
Rattus norvegicus | Retinoid X receptor alpha | Starlite/ChEMBL | References |
Homo sapiens | retinoic acid receptor, beta | Starlite/ChEMBL | References |
Rattus norvegicus | Peroxisome proliferator-activated receptor alpha | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | kringle domain-containing protein | 0.0517 | 0.117 | 0.5 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0858 | 0.6214 | 1 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.0811 | 0.5521 | 1 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0517 | 0.117 | 1 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0517 | 0.117 | 0.5 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0517 | 0.117 | 0.5 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0517 | 0.117 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.1113 | 1 | 0.5 |
Brugia malayi | nuclear hormone receptor | 0.0811 | 0.5521 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0517 | 0.117 | 0.0902 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0517 | 0.117 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0485 | 0.0693 | 0.0411 |
Leishmania major | hypothetical protein, conserved | 0.0517 | 0.117 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0769 | 0.4903 | 0.8578 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 1716.1 nM | In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay was determined | ChEMBL. | 12954061 |
Efficacy (binding) | = 17 % | In vitro evaluation against RXR-alpha in CV-1 cells by cotransfection assay. | ChEMBL. | 12954061 |
Efficacy (binding) | = 17 % | In vitro evaluation against RXR-alpha in CV-1 cells by cotransfection assay. | ChEMBL. | 12954061 |
Efficacy (binding) | = 42 % | In vitro evaluation against RXR-alpha in CV-1 cells by cotransfection assay. | ChEMBL. | 12954061 |
Efficacy (binding) | = 42 % | In vitro evaluation against RXR-alpha in CV-1 cells by cotransfection assay. | ChEMBL. | 12954061 |
Efficacy (binding) | = 52 % | In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay. | ChEMBL. | 12954061 |
Efficacy (binding) | = 145 % | In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay. | ChEMBL. | 12954061 |
IC50 (binding) | = 11.4 nM | Invitro evaluation against RXR-alpha in CV-1 cells by cotransfection assay was determined | ChEMBL. | 12954061 |
IC50 (binding) | = 11.4 nM | Invitro evaluation against RXR-alpha in CV-1 cells by cotransfection assay was determined | ChEMBL. | 12954061 |
Ki (binding) | = 1.6 nM | Binding affinity for Retinoic acid receptor RXR-beta was determined by competing with 3[H]-9-cis-RA | ChEMBL. | 12954061 |
Ki (binding) | = 1.6 nM | Binding affinity for Retinoic acid receptor RXR-beta was determined by competing with 3[H]-9-cis-RA | ChEMBL. | 12954061 |
Ki (binding) | = 2.2 nM | Binding affinity for Retinoic acid receptor RXR-alpha was determined by competing with 3[H]-9-cis-RA | ChEMBL. | 12954061 |
Ki (binding) | = 2.2 nM | Binding affinity for Retinoic acid receptor RXR-alpha was determined by competing with 3[H]-9-cis-RA | ChEMBL. | 12954061 |
Ki (binding) | = 2.5 nM | Binding affinity for Retinoic acid receptor RXR-gamma was determined by competing with 3[H]-9-cis-RA | ChEMBL. | 12954061 |
Ki (binding) | = 2.5 nM | Binding affinity for Retinoic acid receptor RXR-gamma was determined by competing with 3[H]-9-cis-RA | ChEMBL. | 12954061 |
Ki (binding) | = 2569 nM | Binding affinity for Retinoic acid receptor alpha was determined by competing with 3[H]-ATRA | ChEMBL. | 12954061 |
Ki (binding) | = 2569 nM | Binding affinity for Retinoic acid receptor alpha was determined by competing with 3[H]-ATRA | ChEMBL. | 12954061 |
Ki (binding) | = 3149 nM | Binding affinity for Peroxisome proliferator activated receptor gamma was determined | ChEMBL. | 12954061 |
Ki (binding) | = 3149 nM | Binding affinity for Peroxisome proliferator activated receptor gamma was determined | ChEMBL. | 12954061 |
Ki (binding) | = 4064 nM | Binding affinity for Retinoic acid receptor beta was determined by competing with 3[H]-ATRA | ChEMBL. | 12954061 |
Ki (binding) | = 4064 nM | Binding affinity for Retinoic acid receptor beta was determined by competing with 3[H]-ATRA | ChEMBL. | 12954061 |
Ki (binding) | > 10000 nM | Binding affinity for Retinoic acid receptor gamma was determined by competing with 3[H]-ATRA | ChEMBL. | 12954061 |
Ki (binding) | > 10000 nM | Binding affinity for peroxisome Peroxisome proliferator activated receptor alpha was determined | ChEMBL. | 12954061 |
Ki (binding) | > 10000 nM | Binding affinity for Retinoic acid receptor gamma was determined by competing with 3[H]-ATRA | ChEMBL. | 12954061 |
Ki (binding) | > 10000 nM | Binding affinity for peroxisome Peroxisome proliferator activated receptor alpha was determined | ChEMBL. | 12954061 |
Synergy (binding) | = 3 fold | In vitro snergistic elevation of transcriptional activation in CV-1 cells expressing RAR and RXR with 3 nm TTNBP | ChEMBL. | 12954061 |
Synergy (binding) | = 3 fold | In vitro snergistic elevation of transcriptional activation in CV-1 cells expressing RAR and RXR with 3 nm TTNBP | ChEMBL. | 12954061 |
Synergy EC50 (binding) | = 117.4 nM | In vitro evaluation against RXR-alpha/PPAR-gamma in CV-1 cells by cotransfection assay was determined | ChEMBL. | 12954061 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.